Q0512 HCPCS Level II code: Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
Q0512 is the HCPCS code for “Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
Short description: Px sup fee anti-can sub pres
HCPCS · United States
Notes for Q0512
As CMS prints them, with any note Q0512 takes from the headings above it.
Note
- CMS processing note 0129: MMA section 303(e).
Medicare details
The indicators CMS publishes with Q0512 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- DMEPOS fee schedule – Carrier priced (e.g., not otherwise classified, individual determination, carrier discretion, gap-filled amounts)
- Type of service
- Other medical items or services
- BETOS category
- Other drugs
- Added
- Jan 1, 2006
Where Q0512 sits
- 1Q codesTemporary codes
- 2Active code Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q0512 mean?
Q0512 is the HCPCS code for “Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q0512?
CMS lists Q0512’s Medicare coverage as “Special coverage instructions apply” and its pricing as “DMEPOS fee schedule – Carrier priced (e.g., not otherwise classified, individual determination, carrier discretion, gap-filled amounts)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q0512
All Q codesQ0506Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement onlyQ0507Miscellaneous supply or accessory for use with an external ventricular assist deviceQ0508Miscellaneous supply or accessory for use with an implanted ventricular assist deviceQ0509Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part aQ0510Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplantQ0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodQ0513Pharmacy dispensing fee for inhalation drug(s); per 30 daysQ0514Pharmacy dispensing fee for inhalation drug(s); per 90 daysQ0515Injection, sermorelin acetate, 1 microgramQ0516Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-daysQ0517Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-daysQ0518Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days